D. E. Shaw & Co. Inc. Has $31.06 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

D. E. Shaw & Co. Inc. lifted its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 34.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 884,538 shares of the company’s stock after buying an additional 226,514 shares during the quarter. D. E. Shaw & Co. Inc. owned about 1.17% of IDEAYA Biosciences worth $31,056,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Covestor Ltd grew its holdings in IDEAYA Biosciences by 9,225.0% during the 1st quarter. Covestor Ltd now owns 1,119 shares of the company’s stock worth $49,000 after acquiring an additional 1,107 shares during the period. Quest Partners LLC acquired a new stake in shares of IDEAYA Biosciences during the second quarter worth $41,000. Comerica Bank increased its holdings in IDEAYA Biosciences by 723.5% in the first quarter. Comerica Bank now owns 1,507 shares of the company’s stock valued at $66,000 after purchasing an additional 1,324 shares during the last quarter. JTC Employer Solutions Trustee Ltd acquired a new position in IDEAYA Biosciences in the first quarter valued at about $67,000. Finally, Daiwa Securities Group Inc. boosted its holdings in IDEAYA Biosciences by 637.9% during the second quarter. Daiwa Securities Group Inc. now owns 1,948 shares of the company’s stock worth $68,000 after buying an additional 1,684 shares during the last quarter. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Stock Performance

Shares of IDEAYA Biosciences stock opened at $30.80 on Friday. The firm has a market cap of $2.33 billion, a PE ratio of -15.32 and a beta of 0.84. The business’s 50 day simple moving average is $37.92 and its 200 day simple moving average is $39.23. IDEAYA Biosciences, Inc. has a 52-week low of $23.41 and a 52-week high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.14). IDEAYA Biosciences had a negative return on equity of 20.52% and a negative net margin of 483.05%. During the same quarter in the prior year, the business posted ($0.50) earnings per share. As a group, equities research analysts predict that IDEAYA Biosciences, Inc. will post -2.51 EPS for the current year.

Analyst Upgrades and Downgrades

IDYA has been the subject of a number of recent analyst reports. Mizuho started coverage on IDEAYA Biosciences in a research note on Monday, July 8th. They issued an “outperform” rating and a $50.00 price target for the company. JPMorgan Chase & Co. reduced their price target on shares of IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Wedbush decreased their price target on shares of IDEAYA Biosciences from $54.00 to $52.00 and set an “outperform” rating for the company in a report on Tuesday, September 24th. Stifel Nicolaus raised their price objective on IDEAYA Biosciences from $63.00 to $68.00 and gave the stock a “buy” rating in a research note on Tuesday, September 10th. Finally, Lifesci Capital raised IDEAYA Biosciences to a “strong-buy” rating in a research note on Monday, July 29th. Twelve research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $56.00.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.